KRYS
Price
$183.02
Change
+$2.45 (+1.36%)
Updated
Oct 7 closing price
Capitalization
5.3B
33 days until earnings call
VRDN
Price
$21.00
Change
+$0.17 (+0.82%)
Updated
Oct 7 closing price
Capitalization
1.71B
41 days until earnings call
Interact to see
Advertisement

KRYS vs VRDN

Header iconKRYS vs VRDN Comparison
Open Charts KRYS vs VRDNBanner chart's image
Krystal Biotech
Price$183.02
Change+$2.45 (+1.36%)
Volume$212.15K
Capitalization5.3B
Viridian Therapeutics
Price$21.00
Change+$0.17 (+0.82%)
Volume$564.73K
Capitalization1.71B
KRYS vs VRDN Comparison Chart in %
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. VRDN commentary
Oct 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a StrongBuy and VRDN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 08, 2025
Stock price -- (KRYS: $183.02 vs. VRDN: $21.00)
Brand notoriety: KRYS and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 56% vs. VRDN: 71%
Market capitalization -- KRYS: $5.3B vs. VRDN: $1.71B
KRYS [@Biotechnology] is valued at $5.3B. VRDN’s [@Biotechnology] market capitalization is $1.71B. The market cap for tickers in the [@Biotechnology] industry ranges from $105.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 1 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • KRYS’s FA Score: 1 green, 4 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, KRYS is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 7 TA indicator(s) are bullish while VRDN’s TA Score has 4 bullish TA indicator(s).

  • KRYS’s TA Score: 7 bullish, 3 bearish.
  • VRDN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, KRYS is a better buy in the short-term than VRDN.

Price Growth

KRYS (@Biotechnology) experienced а +3.68% price change this week, while VRDN (@Biotechnology) price change was -2.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.19%. For the same industry, the average monthly price growth was +15.97%, and the average quarterly price growth was +89.17%.

Reported Earning Dates

KRYS is expected to report earnings on Nov 10, 2025.

VRDN is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+8.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($5.3B) has a higher market cap than VRDN($1.72B). KRYS YTD gains are higher at: 16.826 vs. VRDN (9.546). KRYS has higher annual earnings (EBITDA): 158M vs. VRDN (-340.62M). KRYS has more cash in the bank: 682M vs. VRDN (563M). KRYS has less debt than VRDN: KRYS (9.68M) vs VRDN (21.3M). KRYS has higher revenues than VRDN: KRYS (359M) vs VRDN (305K).
KRYSVRDNKRYS / VRDN
Capitalization5.3B1.72B309%
EBITDA158M-340.62M-46%
Gain YTD16.8269.546176%
P/E Ratio37.20N/A-
Revenue359M305K117,705%
Total Cash682M563M121%
Total Debt9.68M21.3M45%
FUNDAMENTALS RATINGS
KRYS vs VRDN: Fundamental Ratings
KRYS
VRDN
OUTLOOK RATING
1..100
1766
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
3178
SMR RATING
1..100
5499
PRICE GROWTH RATING
1..100
4542
P/E GROWTH RATING
1..100
72100
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KRYS's Valuation (79) in the Pharmaceuticals Major industry is in the same range as VRDN (92) in the Biotechnology industry. This means that KRYS’s stock grew similarly to VRDN’s over the last 12 months.

KRYS's Profit vs Risk Rating (31) in the Pharmaceuticals Major industry is somewhat better than the same rating for VRDN (78) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than VRDN’s over the last 12 months.

KRYS's SMR Rating (54) in the Pharmaceuticals Major industry is somewhat better than the same rating for VRDN (99) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than VRDN’s over the last 12 months.

VRDN's Price Growth Rating (42) in the Biotechnology industry is in the same range as KRYS (45) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's P/E Growth Rating (72) in the Pharmaceuticals Major industry is in the same range as VRDN (100) in the Biotechnology industry. This means that KRYS’s stock grew similarly to VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSVRDN
RSI
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 6 days ago
78%
Bullish Trend 10 days ago
81%
Declines
ODDS (%)
Bearish Trend 14 days ago
75%
Bearish Trend 7 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
80%
Aroon
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JDIRX55.83N/A
N/A
Janus Henderson Overseas R
HIAHX16.05N/A
N/A
Hartford Healthcare HLS IA
WPOIX12.42N/A
N/A
Weitz Partners III Opportunity Investor
NWFFX95.14-0.30
-0.31%
American Funds New World F1
RYOFX15.41-0.32
-2.03%
Royce Small-Cap Opportunity Svc

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with SYRE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
+0.82%
SYRE - VRDN
57%
Loosely correlated
-3.90%
NUVL - VRDN
56%
Loosely correlated
-0.56%
KRYS - VRDN
52%
Loosely correlated
+1.36%
CRNX - VRDN
52%
Loosely correlated
+1.97%
NRIX - VRDN
52%
Loosely correlated
-1.21%
More